Search

Displaying results 6231 - 6240 of 10000 in total
  1. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  2. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  3. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

  4. Drug

    Dalzanemdor

    go.drugbank.com/drugs/DB21549
    Investigational

    Dalzanemdor is under investigation in clinical trial NCT05655520 (A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease). … Dalzanemdor has a monoisotopic molecular weight of 456.32 Da.

  5. Drug

    Crobenetine

    go.drugbank.com/drugs/DB21095
    Investigational

    Crobenetine has a monoisotopic molecular weight of 379.25 Da. … Crobenetine is a small molecule drug.

  6. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … and other lipids from cells including those in the arterial wall.

  7. Drug

    QazCovid-in

    go.drugbank.com/drugs/DB16441
    Investigational

    The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628]. … It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].

  8. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  9. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies). Amredobresib has a monoisotopic molecular weight of 467.25 Da. … The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

  10. Drug

    Tegtociclib

    go.drugbank.com/drugs/DB21635
    Investigational

    Tegtociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor. … Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid